Ultragenyx Pharmaceutical Inc. Form 4 Filings

Ultragenyx Pharmaceutical Inc. (RARE) reports that Theodore Alan Huizenga, its SVP and Chief Accounting Officer, reported a sale of 161 shares of common stock on September 3, 2026 at $13.99 per share. The shares were sold to pay required tax withholdings from vesting RSUs, and he now holds 69,146 shares directly, including 396 shares acquired under the company’s Amended and Restated Employee Stock Purchase Plan and previously reported unvested RSUs. No Rule 10b5-1 trading plan is reported.

Ultragenyx Pharmaceutical Inc. EVP and Chief Legal Officer Karah Herdman Parschauer reported a sale of 1,900 shares of common stock on August 3, 2026 at $24.92 per share under a Rule 10b5-1 trading plan. Following this transaction, she directly holds 92,562 shares, including previously reported RSU-based shares subject to vesting conditions.

Ultragenyx Pharmaceutical Inc. reports that Chief Financial Officer Howard Horn sold 4,696 shares of common stock on August 3, 2026 at $24.92 per share in an open-market or private transaction under a Rule 10b5-1 trading plan, and now directly holds 96,295 shares, including shares underlying RSUs that remain subject to vesting conditions.

Ultragenyx Pharmaceutical Inc. Chief Financial Officer Howard Horn reported an open-market sale of 4,698 shares of common stock at a price of $33.13 per share. After this transaction, he directly owns 100,991 shares. His reported holdings include shares underlying previously granted RSUs that vest over time.

Ultragenyx Pharmaceutical Inc. director Sanders Corazon (Corsee) D. sold 2,000 shares of Common Stock in an open-market transaction at $25.05 per share. After this sale, the director directly holds 21,095 shares. The reported holdings include previously disclosed RSUs that will vest over time.

Ultragenyx Pharmaceutical Inc. executive Karah Herdman Parschauer reported an open-market sale of 1,899 shares of common stock at $24.62 per share. After this transaction, she directly holds 94,462 shares. Her holdings include 646 shares acquired under the company’s Employee Stock Purchase Plan and previously reported RSU-based common stock that remains subject to vesting conditions.

Ultragenyx Pharmaceutical Inc. Chief Financial Officer Howard Horn reported an open-market sale of common stock. On June 1, 2026, he sold 4,653 shares at a price of $23.77 per share. After this transaction, he directly holds 105,689 shares, which include previously reported shares underlying RSUs that remain subject to vesting conditions.

Ultragenyx Pharmaceutical Inc. director Matthew K. Fust reported receiving equity compensation in the form of both restricted stock units and stock options. He was granted 7,751 shares of Common Stock as Restricted Stock Units under the company’s 2023 Incentive Plan, bringing his direct common stock holdings to 33,696 shares following the award.

He was also granted a stock option for 14,058 shares of Common Stock with an exercise price of $25.80 per share, representing his full reported option position after this grant. Both the RSUs and the stock option vest in full on the earlier of the company’s next Annual Meeting of Stockholders or May 14, 2027.

Ultragenyx Pharmaceutical Inc. director Shehnaaz Suliman reported a mix of equity awards and a share sale. On May 14, 2026, she received 7,751 Restricted Stock Units under the company’s 2023 Incentive Plan and a stock option for 14,058 shares with a $25.80 exercise price, both vesting in full on the earlier of the next Annual Meeting of Stockholders or May 14, 2027. On May 18, 2026, she executed an open-market sale of 5,740 shares of common stock at $25.12 per share, leaving her with 27,951 common shares held directly after the sale.

Ultragenyx Pharmaceutical Inc. director Ray Amrit reported new equity awards consisting of both restricted stock units and stock options. He received 7,751 shares of Common Stock as Restricted Stock Units granted under the Company’s 2023 Incentive Plan. After this award, he directly holds 31,116 shares of Common Stock.

Amrit was also granted a stock option covering 14,058 shares of Common Stock at an exercise price of $25.80 per share, expiring on May 14, 2036. Both the RSUs and the option vest in full on the earlier of the Company’s next Annual Meeting of Stockholders or May 14, 2027, making this a routine, compensation-related acquisition rather than an open-market purchase.

Ultragenyx Pharmaceutical Inc. director Sanders Corazon (Corsee) D. received new equity awards as part of compensation. On May 14, 2026, the director acquired 7,751 shares of common stock through an award of restricted stock units under the company’s 2023 Incentive Plan, bringing direct holdings to 23,095 shares.

On the same date, the director was granted a stock option for 14,058 shares of common stock at an exercise price of $25.80 per share, expiring on May 14, 2036. Both the RSUs and the option vest in full on the earlier of the company’s next annual meeting of stockholders or May 14, 2027, making these routine, time-based equity incentives rather than open-market purchases.

Ultragenyx Pharmaceutical Inc. director Michael Narachi received equity compensation in the form of restricted stock units and options. He was granted 7,751 RSUs that vest in full on the earlier of the company’s next Annual Meeting of Stockholders or May 14, 2027. He also received stock options for 14,058 shares of common stock at an exercise price of $25.80 per share, vesting on the same schedule and expiring on May 14, 2036. Following the RSU grant, his direct common stock holdings increased to 40,441 shares.

Ultragenyx Pharmaceutical Inc. director Daniel G. Welch reported equity awards from the company. He received 7,751 shares of Common Stock as a grant of restricted stock units (RSUs) under the 2023 Incentive Plan, with no cash paid per share, bringing his direct Common Stock holdings to 40,441 shares.

He was also granted a stock option covering 14,058 shares of Common Stock at an exercise price of $25.80 per share, expiring on May 14, 2036. Both the RSUs and the option vest in full on the earlier of the company’s next Annual Meeting of Stockholders or May 14, 2027.

Ultragenyx Pharmaceutical Inc. director Deborah Dunsire received new equity awards as part of her compensation. She was granted 7,751 shares of Common Stock in the form of restricted stock units that vest in full on the earlier of the company’s next Annual Meeting of Stockholders or May 14, 2027. She also received stock options for 14,058 shares of Common Stock at an exercise price of $25.80 per share, expiring on May 14, 2036, with the options vesting on the same schedule. Following these awards, she directly holds 38,566 shares of Common Stock and 14,058 stock options.

Ultragenyx Pharmaceutical Inc. executive Eric Crombez, EVP and Chief Medical Officer, sold 344 shares of common stock at $24.96 per share on May 5, 2026. According to the footnotes, these shares were sold to pay required tax withholdings related to the vesting of restricted stock units (RSUs). After this tax-related sale, Crombez directly holds 111,189 shares of Ultragenyx common stock.

Ultragenyx Pharmaceutical Inc.’s Chief Financial Officer Howard Horn reported an open-market sale of 4,683 shares of common stock at $24.90 per share. After this transaction, he directly owns 110,342 shares, which the disclosure notes include shares underlying RSUs that are subject to vesting conditions.

Ultragenyx Pharmaceutical Inc. reported that SVP and Chief Accounting Officer Theodore Alan Huizenga received an equity compensation grant. He was awarded 20,241 shares of common stock in the form of restricted stock units, increasing his direct holdings to 68,911 shares. These RSUs vest in four equal annual installments on each anniversary of the grant date, becoming fully vested after four years.

He also received a stock option for 7,348 shares of common stock with an exercise price of $24.61 per share, expiring on April 22, 2036. One quarter of the option vests on the first anniversary of the grant date, with the remainder vesting in equal monthly installments thereafter.

Ultragenyx Pharmaceutical Inc. President & CEO Emil D. Kakkis reported new equity compensation awards and updated indirect holdings. He received 76,745 Restricted Stock Units (RSUs) under the company’s 2023 Incentive Plan, which vest in four equal annual installments from the grant date.

He was also granted a stock option for 132,693 shares of common stock at an exercise price of $24.52 per share, vesting 25% on the first anniversary of the grant and the remainder monthly thereafter until 2036-04-16. Following these awards, he directly holds 735,739 shares of common stock.

The filing also reflects updated indirect ownership, including 1,758,985 shares held through the Emil Kakkis and Jenny Soriano Living Trust and an aggregate 400,000 shares contributed to two grantor retained annuity trusts (GRATs). These changes reflect compensation grants and estate-planning transfers rather than open-market trades.

Ultragenyx Pharmaceutical Inc. reported that officer Dennis Karl Huang received equity awards consisting of common stock and stock options. He was granted 23,116 shares of common stock as Restricted Stock Units (RSUs), bringing his direct common stock holdings to 147,845 shares after the award.

The RSUs were granted under the company’s 2023 Incentive Plan and vest in four equal annual installments on each anniversary of the grant date. Huang was also granted 79,936 stock options with an exercise price of $24.52 per share, expiring on April 16, 2036, which vest over four years with 1/4 vesting after one year and the remainder vesting monthly.

Ultragenyx Pharmaceutical Inc. executive John Richard Pinion received new equity awards in the form of restricted stock units and stock options. He was granted 23,116 shares of common stock as RSUs under the company’s 2023 Incentive Plan, bringing his direct common stock holdings to 133,142 shares after the award. These RSUs vest in four equal annual installments on each anniversary of the grant date.

He also received a stock option covering 79,936 shares of common stock at an exercise price of $24.52 per share, expiring on April 16, 2036. One quarter of the option vests on the first anniversary of the grant date, with the remainder vesting in equal monthly installments over the following three years.

Ultragenyx Pharmaceutical Inc. reported that EVP and Chief Legal Officer Karah Herdman Parschauer received an equity compensation package consisting of restricted stock units and stock options. She was granted 28,895 RSUs under the company’s 2023 Incentive Plan, vesting 25% on each anniversary of the grant date over four years. She was also granted a stock option for 49,960 shares of common stock at an exercise price of $24.52 per share, expiring on April 16, 2036, with 25% vesting after one year and the remainder vesting monthly thereafter. Following these grants, she directly holds 95,715 shares of common stock, including shares underlying previously reported RSUs that remain subject to vesting conditions.

Ultragenyx Pharmaceutical EVP & Chief Commercial Officer Erik Harris received new equity awards. He was granted 28,895 shares of common stock in the form of restricted stock units (RSUs) under the company’s 2023 Incentive Plan, bringing his direct common stock holdings to 118,410 shares.

He also received a stock option for 49,960 shares of common stock at an exercise price of $24.52 per share, expiring on April 16, 2036. The RSUs vest in four equal annual installments, while the option vests 25% on the first anniversary of the grant date and 1/48 monthly thereafter.

Ultragenyx Pharmaceutical EVP and Chief Medical Officer Eric Crombez received new equity awards as part of his compensation. He was granted 34,674 shares of Common Stock in the form of Restricted Stock Units (RSUs) under the company’s 2023 Incentive Plan.

The RSUs vest over four years, with one-quarter of the underlying shares vesting on each anniversary of the grant date. Crombez also received a stock option for 59,952 shares of Common Stock at an exercise price of $24.52 per share, expiring on April 16, 2036.

The option vests with one-quarter of the shares on the first anniversary of the grant date and the remainder in equal monthly installments thereafter. Following these awards, Crombez directly holds 110,975 shares of Common Stock, including previously reported RSU-based holdings subject to vesting conditions.

Ultragenyx Pharmaceutical Inc. Chief Financial Officer Howard Horn received new equity awards. He was granted 34,674 shares of common stock in the form of restricted stock units under the company’s 2023 Incentive Plan, bringing his direct common stock holdings to 115,025 shares.

The RSUs vest over four years, with one-quarter of the shares vesting on each anniversary of the grant date until fully vested on the fourth anniversary. Horn was also granted stock options for 59,952 shares of common stock at an exercise price of $24.52 per share, expiring on April 16, 2036. These options vest as to one-quarter of the shares on the first anniversary of the grant date and then in equal monthly installments over the following three years.

Ultragenyx Pharmaceutical Inc.’s Chief Financial Officer, Howard Horn, sold 4,683 shares of common stock in an open-market transaction. The shares were sold at $20.97 each. After this sale, he directly holds 80,351 shares, which include previously reported RSU-based shares that vest over time.

Ultragenyx Pharmaceutical Inc.’s EVP and Chief Legal Officer, Karah Herdman Parschauer, reported open-market sales of company common stock. She sold 6,018 shares on March 6, 2026 at $21.40 per share and 3,508 shares on March 10, 2026 at $22.67 per share, for total reported sales of 9,526 shares. Following these transactions, she directly holds 66,820 shares of common stock, which include previously reported shares underlying restricted stock units that are subject to vesting conditions.

Ultragenyx Pharmaceutical Inc. officer John Richard Pinion reported stock-based compensation activity and a related tax sale. On March 1, 2026, he acquired 11,137 shares of common stock at $0.00 per share through the conversion of previously granted performance stock units after certification of performance metrics.

On March 2, 2026, he sold 10,029 common shares in an open-market transaction at a weighted average price of $22.80 per share, in multiple trades between $22.54 and $23.11, to pay required tax withholdings tied to RSU vesting. Following these transactions, he directly owned 110,026 common shares, including 490 shares from the employee stock purchase plan and shares underlying RSUs subject to vesting conditions.

Ultragenyx Pharmaceutical EVP & Chief Commercial Officer Erik Harris reported both an equity award and a related share sale. On March 1, 2026, he acquired 11,643 shares of common stock at $0.00 per share from previously granted performance stock units that converted upon certification of performance metrics.

On March 2, 2026, he sold 10,539 shares of common stock at a weighted-average price of $22.80 per share to cover required tax withholdings tied to restricted stock unit vesting. After these transactions, he directly held 89,515 shares of common stock, plus additional RSUs subject to vesting conditions.

Ultragenyx Pharmaceutical President & CEO Emil Kakkis reported equity compensation activity and a related tax sale. On March 1, 2026, previously granted performance stock units converted into 71,177 shares of common stock upon certification of performance metrics. On March 2, 2026, he sold 54,404 shares of common stock at a weighted average price of $22.80 per share to cover required tax withholdings from RSU vesting. After these transactions, he directly owned 658,994 shares and indirectly held 2,158,985 shares through the Emil Kakkis and Jenny Soriano Living Trust.

Ultragenyx Pharmaceutical EVP and Chief Legal Officer Karah Herdman Parschauer reported both a stock grant and a related share sale. On March 1, 2026, she acquired 11,137 shares of common stock at no cost through conversion of previously granted performance stock units upon certification of performance metrics. On March 2, 2026, she sold 8,135 shares of common stock in an open-market transaction at a weighted average price of $22.80 per share, in multiple trades between $22.54 and $23.11, to cover required tax withholdings due to vesting of restricted stock units. After these transactions, she directly held 76,346 shares, including shares acquired under the company’s employee stock purchase plan and shares underlying unvested restricted stock units subject to vesting conditions.

Ultragenyx Pharmaceutical Inc. senior vice president and chief accounting officer Theodore Alan Huizenga reported two common stock transactions. He completed an open-market sale of 1,632 shares at a weighted average price of $22.80 per share, primarily to cover required tax withholdings from vesting restricted stock units (RSUs).

In a related move, he also disposed of 148 shares at $23.39 per share through share surrender to satisfy additional tax obligations tied to RSU vesting. Following these tax-related and open-market transactions, he directly owned a total of 48,670 shares of Ultragenyx common stock, which includes previously reported unvested RSUs subject to vesting conditions.

Ultragenyx Pharmaceutical Inc. Chief Financial Officer Howard Horn reported a mix of stock awards and sales. On March 1, 2026, he acquired 6,143 shares of common stock at no cost when previously granted performance stock units converted after the performance metric was certified. On March 2–3, 2026, he sold a total of 10,044 shares in open-market transactions at prices around the low‑$20s per share, with some shares sold to cover required tax withholdings from restricted stock unit vesting. After these transactions, he directly owned 85,034 shares of Ultragenyx common stock.

Ultragenyx Pharmaceutical EVP and Chief Medical Officer Eric Crombez reported a mix of stock award and sale transactions. On March 1, 2026, he acquired 11,643 shares of common stock at $0.00 per share through a grant, as previously granted performance stock units converted upon certification of performance metrics. On March 2, 2026, he executed an open-market sale of 7,029 shares of common stock at a weighted average price of $22.80 per share, with actual prices ranging from $22.54 to $23.11. A footnote states these shares were sold to pay required tax withholdings related to the vesting of restricted stock units. Following these transactions, Crombez directly held 76,301 shares of Ultragenyx common stock, which includes shares acquired under the company’s employee stock purchase plan and shares underlying restricted stock units that remain subject to vesting conditions.

Ultragenyx Pharmaceutical executive Dennis Karl Huang reported equity compensation activity involving company common stock. On March 1, 2026, he acquired 11,137 shares at a stated price of $0.00 per share through a grant/award, when previously granted performance stock units converted upon certification of a performance metric.

On March 2, 2026, he disposed of 999 shares at $23.39 per share, surrendering them back to Ultragenyx to cover required tax withholdings tied to restricted stock unit vesting. After these transactions, he directly owned 124,729 common shares.

Ultragenyx Pharmaceutical Inc.'s Chief Financial Officer, Howard Horn, reported a stock sale. On 02/02/2026, he sold 3,061 shares of Ultragenyx common stock at a price of $23.56 per share.

After this transaction, he beneficially owns 88,935 shares of common stock. This figure includes previously reported shares underlying restricted stock units (RSUs) that were granted to him and are still subject to vesting conditions.

Ultragenyx Pharmaceutical (RARE) insider activity: The company’s Chief Financial Officer reported a sale of common stock on 10/13/2025. The filing shows 7,942 shares were sold at $31.51 per share.

According to the explanation, these shares were sold to pay required tax withholdings related to the vesting of restricted stock units (RSUs). Following the transaction, the reporting person beneficially owned 98,227 shares. The ownership is listed as direct.

The filing notes that the remaining amount includes previously reported shares underlying RSUs that are subject to vesting conditions.